European Journal of Epidemiology

, Volume 34, Issue 2, pp 163–172 | Cite as

Contribution of the OC Sensor® immunoassay in comparison to the Hemoccult II® guaiac-test in organized colorectal cancer screening

  • Carole VitelliusEmail author
  • Margot Laly
  • Anne-Sophie Banaszuk
  • Isabelle Deherce
  • Nathanaëlle Cornet
  • Sandrine Bertrais
  • Patrick Saulnier
  • François-Xavier Caroli-Bosc


Colorectal cancer (CRC) is a major cause of cancer-related death of worldwide with high incidence and mortality rate, accessible to a screening program in France, first with guaiac- based fecal occult blood test (g-FOBT) then with fecal immunochemical tests (FIT), since 2015, because of better accuracy. The aim of our study was to compare the characteristics of screen-detected lesions in two successive CRC screening campaigns, using two different tests (Hemoccult II® and OC Sensor®) in the department of Maine-et-Loire, and to precise the performance of these tests [participation rate, detection rates (DR), positive predictive value (PPV)]. Participants, invited by CAP SANTE 49, with polyps or cancer at the colonoscopy after a positive screening test between 01/01/2013 and 31/12/2016 were included. A guaiac-based fecal occult blood test (g-FOBT) was used from January 2013 to December 2014 and a FIT was used from June 2015 to December 2016). 2575 participants, 642 in g-FOBT group and 1933 in FIT group had lesions. Participation rate was not different between tests (p = 0.104), whereas DR and PPV were statistically higher in FIT for all lesions (2.61, 95% CI [2.50–2.70] vs 0.93, 95% CI [0.90–1.00], p < 0.0001 and 64.84, 95% CI [63.10–66.60], 50.00, 95% CI [47.30–52.70], p < 0.0001 respectively). FIT detects more precancerous lesions (adenomas, p < 0.001, and advanced adenomas, p < 0.001) than g-FOBT but g-FOBT detects more serrated polyps (p = 0.025). AAs were more in right colon in FIT than g-FOBT (p = 0.035). No different participation rate was detected between FIT and g-FOBT but DR and PPV of all lesions was higher with FIT.


Colorectal cancer Screening Immunochemical test Performance test 


  1. 1.
    Jéhannin-Ligier K, Dantony E, Bossard N, Molinié F, Defossez G, Daubisse-Marliac L, Delafosse P,, Remontet L, Uhry Z. Projection de l’incidence et de la mortalité par cancer en France métropolitaine en 2017. Rapport technique. Saint-Maurice: Santé publique France; 2017 [cited 2018 June 21].
  2. 2.
    Holleczek B, Rossi S, Domenic A, Innos K, Minicozzi P, Francisci S, et al. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007—results from the EUROCARE-5 study. Eur J Cancer. 1990;2015(51):2158–68.Google Scholar
  3. 3.
    Cowppli-Bony A, Uhry Z, Remontet L, Guizard A-V, Voirin N, Monnereau A, Bouvier A-M, Colonna M, Bossard N, Woronoff A-S, Grosclaude P. Survie des personnes atteintes de cancer en France métropolitaine, 1989–2013. Partie 1—Tumeurs solides. Saint-Maurice: Institut de veille sanitaire; 2016 [cited 2018 June 21].
  4. 4.
    Selby JV. Effect of fecal occult blood testing on mortality from colorectal cancer: a case–control study. Ann Intern Med. 1993;118:1.CrossRefGoogle Scholar
  5. 5.
    Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–7.CrossRefGoogle Scholar
  6. 6.
    Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–71.CrossRefGoogle Scholar
  7. 7.
    Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 2004;126:1674–80.CrossRefGoogle Scholar
  8. 8.
    Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365–71.CrossRefGoogle Scholar
  9. 9.
    Tinmouth J, Lansdorp-Vogelaar I, Allison JE. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. Gut. 2015;64:1327–37.CrossRefGoogle Scholar
  10. 10.
    Chiu H-M, Chen SL-S, Yen AM-F, Chiu SY-H, Fann JC-Y, Lee Y-C, et al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. Cancer. 2015;121:3221–9.CrossRefGoogle Scholar
  11. 11.
    Zorzi M, Fedeli U, Schievano E, Bovo E, Guzzinati S, Baracco S, et al. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. Gut. 2015;64:784–90.CrossRefGoogle Scholar
  12. 12.
    Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014;160:171.CrossRefGoogle Scholar
  13. 13.
    Guittet L, Bouvier V, Mariotte N, Vallee JP, Levillain R, Tichet J, et al. Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location. Br J Cancer. 2009;100:1230–5.CrossRefGoogle Scholar
  14. 14.
    HAS. Place des tests immunologiques de recherche de sang occulte dans les selles (iFOBT)dans le programme de dépistage organisé du cancer colorectal en france. 2008 [cited 2018 Jun 21].
  15. 15.
    Chaptini L, Chaaya A, Depalma F, Hunter K, Peikin S, Laine L. Variation in polyp size estimation among endoscopists and impact on surveillance intervals. Gastrointest Endosc. 2014;80:652–9.CrossRefGoogle Scholar
  16. 16.
    Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRefGoogle Scholar
  17. 17.
    Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O’Brien MJ, Levin B, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on colorectal cancer and the American Cancer Society. Gastroenterology. 2006;130:1872–85.CrossRefGoogle Scholar
  18. 18.
    Rosman AS, Korsten MA. Effect of verification bias on the sensitivity of fecal occult blood testing: a meta-analysis. J Gen Intern Med. 2010;25:1211–21.CrossRefGoogle Scholar
  19. 19.
    Launois R, Le Moine J-G, Uzzan B, Fiestas Navarrete LI, Benamouzig R. Systematic review and bivariate/HSROC random-effect meta-analysis of immunochemical and guaiac-based fecal occult blood tests for colorectal cancer screening. Eur J Gastroenterol Hepatol. 2014;26:978–89.CrossRefGoogle Scholar
  20. 20.
    Taux de participation au programme de dépistage organisé du cancer colorectal 2015–2016/Indicateurs d’évaluation/Evaluation du programme de dépistage du cancer colorectal/Evaluation des programmes de dépistage des cancers/Cancers/Maladies chroniques et traumatismes/Dossiers thématiques/Accueil [cited 2018 June 21].
  21. 21.
    van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135:82–90.CrossRefGoogle Scholar
  22. 22.
    Federici A, Giorgi Rossi P, Borgia P, Bartolozzi F, Farchi S, Gausticchi G. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. J Med Screen. 2005;12:83–8.CrossRefGoogle Scholar
  23. 23.
    Piette C, Durand G, Bretagne J-F, Faivre J. Additional mailing phase for FIT after a medical offer phase: the best way to improve compliance with colorectal cancer screening in France. Dig Liver Dis. 2017;49:308–11.CrossRefGoogle Scholar
  24. 24.
    Ko CW, Dominitz JA, Nguyen TD. Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical-based tests. Am J Med. 2003;115:111–4.CrossRefGoogle Scholar
  25. 25.
    Corley DA, Jensen CD, Quinn VP, Doubeni CA, Zauber AG, Lee JK, et al. Association between time to colonoscopy after a positive fecal test result and risk of colorectal cancer and cancer stage at diagnosis. JAMA. 2017;317:1631–41.CrossRefGoogle Scholar
  26. 26.
    Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 1996;334:155–9.CrossRefGoogle Scholar
  27. 27.
    de Wijkerslooth TR, Stoop EM, Bossuyt PM, Meijer GA, van Ballegooijen M, van Roon AHC, et al. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol. 2012;107:1570–8.CrossRefGoogle Scholar
  28. 28.
    Castiglione G, Zappa M, Grazzini G, Mazzotta A, Biagini M, Salvadori P, et al. Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer. Br J Cancer. 1996;74:141–4.CrossRefGoogle Scholar
  29. 29.
    Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsène D, Boutreux S, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut. 2007;56:210–4.CrossRefGoogle Scholar
  30. 30.
    Levi Z, Birkenfeld S, Vilkin A, Bar-Chana M, Lifshitz I, Chared M, et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer. 2011;128:2415–24.CrossRefGoogle Scholar
  31. 31.
    Nakama H, Kamijo N, Abdul Fattah AS, Zhang B. Validity of immunological faecal occult blood screening for colorectal cancer: a follow up study. J Med Screen. 1996;3:63–5.CrossRefGoogle Scholar
  32. 32.
    Robinson MH, Marks CG, Farrands PA, Thomas WM, Hardcastle JD. Population screening for colorectal cancer: comparison between guaiac and immunological faecal occult blood tests. Br J Surg. 1994;81:448–51.CrossRefGoogle Scholar
  33. 33.
    Petrelli N, Michalek AM, Freedman A, Baroni M, Mink I, Rodriguez-Bigas M. Immunochemical versus guaiac occult blood stool tests: results of a community-based screening program. Surg Oncol. 1994;3:27–36.CrossRefGoogle Scholar
  34. 34.
    Haug U, Knudsen AB, Brenner H, Kuntz KM. Is fecal occult blood testing more sensitive for left- versus right-sided colorectal neoplasia? A systematic literature review. Expert Rev Mol Diagn. 2011;11:605–16.CrossRefGoogle Scholar
  35. 35.
    Hirai HW, Tsoi KKF, Chan JYC, Wong SH, Ching JYL, Wong MCS, et al. Systematic review with meta-analysis: faecal occult blood tests show lower colorectal cancer detection rates in the proximal colon in colonoscopy-verified diagnostic studies. Aliment Pharmacol Ther. 2016;43:755–64.CrossRefGoogle Scholar
  36. 36.
    Graser A, Stieber P, Nagel D, Schäfer C, Horst D, Becker CR, et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut. 2009;58:241–8.CrossRefGoogle Scholar
  37. 37.
    Jouve JL, Remontet L, Dancourt V, Lejeune C, Benhamiche AM, Faivre J, et al. Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening. Br J Cancer. 2001;84:1477–81.CrossRefGoogle Scholar
  38. 38.
    Portillo I, Arana-Arri E, Idigoras I, Bilbao I, Martínez-Indart L, Bujanda L, et al. Colorectal and interval cancers of the Colorectal Cancer Screening Program in the Basque Country (Spain). World J Gastroenterol. 2017;23:2731–42.CrossRefGoogle Scholar
  39. 39.
    Abdeljawad K, Vemulapalli KC, Kahi CJ, Cummings OW, Snover DC, Rex DK. Sessile serrated polyp prevalence determined by a colonoscopist with a high lesion detection rate and an experienced pathologist. Gastrointest Endosc. 2015;81:517–24.CrossRefGoogle Scholar
  40. 40.
    East JE, Atkin WS, Bateman AC, Clark SK, Dolwani S, Ket SN, et al. British Society of Gastroenterology position statement on serrated polyps in the colon and rectum. Gut. 2017;66:1181–96.CrossRefGoogle Scholar
  41. 41.
    Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012;107:1315–29 (quiz 1314, 1330).CrossRefGoogle Scholar
  42. 42.
    Ma MX, Bourke MJ. Sessile serrated adenomas: how to detect, characterize and resect. Gut Liver. 2017;11:747–60.CrossRefGoogle Scholar
  43. 43.
    Zorzi M, Senore C, Da Re F, Barca A, Bonelli LA, Cannizzaro R, et al. Detection rate and predictive factors of sessile serrated polyps in an organised colorectal cancer screening programme with immunochemical faecal occult blood test: the EQuIPE study (Evaluating Quality Indicators of the Performance of Endoscopy). Gut. 2017;66:1233–40.CrossRefGoogle Scholar
  44. 44.
    Chang L-C, Shun C-T, Hsu W-F, Tu C-H, Tsai P-Y, Lin B-R, et al. Fecal immunochemical test detects sessile serrated adenomas and polyps with a low level of sensitivity. Clin Gastroenterol Hepatol. 2017;15(872–9):e1.Google Scholar
  45. 45.
    Heigh RI, Yab TC, Taylor WR, Hussain FTN, Smyrk TC, Mahoney DW, et al. Detection of colorectal serrated polyps by stool DNA testing: comparison with fecal immunochemical testing for occult blood (FIT). PLoS ONE. 2014;9:e85659.CrossRefGoogle Scholar
  46. 46.
    Wieten E, Schreuders EH, Grobbee EJ, Nieboer D, Bramer WM, Lansdorp-Vogelaar I, et al. Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis. Gut. 2018.

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  • Carole Vitellius
    • 1
    • 2
    Email author
  • Margot Laly
    • 1
  • Anne-Sophie Banaszuk
    • 2
  • Isabelle Deherce
    • 2
  • Nathanaëlle Cornet
    • 1
  • Sandrine Bertrais
    • 2
  • Patrick Saulnier
    • 4
  • François-Xavier Caroli-Bosc
    • 1
    • 2
    • 3
  1. 1.Service d’Hépato-gastro-entérologieCHU AngersAngers Cedex 09France
  2. 2.HIFIH Laboratory, UNIV AngersUniversité Bretagne LoireAngersFrance
  3. 3.CAP-Santé 49AngersFrance
  4. 4.MINT Laboratory, UNIV Angers, INSERM 1066, CNRS 6021Université Bretagne LoireAngersFrance

Personalised recommendations